ВКВалентина Геннадьевна Каверина

Валентина Геннадьевна Каверина

*This is an algorithmically generated author record based on publicly available information.

Валентина Геннадьевна Каверина has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical and Genetic Characteristics of 114 Russian Children with a Monogenic Non-Sarcomeric Hypertrophic Cardiomyopathy Phenotype

    by L. A. Gandaeva, V. G. Kaverina, E. N. Basargina, A. A. Pushkov, I. V. Silnova, K. V. Savostyanov, Л. А. Гандаева, В. Г. Каверина, Е. Н. Басаргина, А. A. Пушков, et al.

    Introduction . In children, cardiomyopathies with a morphofunctional phenotype similar to sarcomeric hypertrophic cardiomyopathies are associated with various syndromes and diseases in almost half of cases, and for some of these nosologies, etiopathogenetic therapy is currently possible. Aim : to determine the clinical, laboratory-instrumental, and genetic characteristics of the most common monogenic orphan diseases accompanied by a hypertrophic cardiomyopathy phenotype in children. Methods . The study included 335 patients diagnosed with hypertrophic cardiomyopathies who were regularly followed up at the cardiology department of the National Medical Research Center for Children’s Health, Ministry of Health of the Russian Federation, from 2014 to 2025. All patients underwent molecular genetic analysis of target genomic regions containing 420 genes, in which pathogenic variants have been described in patients with a hypertrophic cardiomyopathy phenotype, using high-throughput sequencing. According to the study design, a comparative analysis of the course of the hypertrophic cardiomyopathy phenotype in children was performed based on the etiological cause—within the framework of inherited metabolic disorders, due to mitochondrial pathology, and RAS-pathy syndromes (n=114). Results . Molecular genetic examination of patients with a hypertrophic cardiomyopathy phenotype verified rare hereditary diseases, including mitochondrial disorders (causal variants in mitochondrial or nuclear DNA), Pompe disease, Danon disease, PRKAG2 syndrome, and various RAS-pathy syndromes. A comparative characterization was performed, showing a high frequency of the hypertrophic cardiomyopathy phenotype in children with early-onset RAS-pathy syndromes. Myocardial hypertrophy exceeding 30 mm was rarely recorded; a symmetric form of the disease was significantly more common in mitochondrial pathology, asymmetric in RAS-pathy syndromes, and biventricular in inherited metabolic disorders. In addition to myocardial hypertrophy, patients with inherited metabolic disorders and mitochondrial pathology exhibited left ventricular dilation and reduced contractility. Patients with RAS-pathy syndromes had more pronounced (grade II–III) mitral regurgitation and a high frequency of pulmonary valve insufficiency (30.8%). Wolff–Parkinson–White syndrome (WPW) phenomenon and nonsustained supraventricular tachycardia were recorded in inherited metabolic disorders. In mitochondrial pathology, an increase in creatine phosphokinase-MB (CK-MB) with normal CK levels was noted; in inherited metabolic disorders, high values of CK, lactate dehydrogenase, and transaminases were observed. No significant difference in the frequency of elevation or in NT-proBNP levels was found between patients. Surgical treatment in the form of septal myectomy was performed mainly in RAS-pathy syndromes (23; 20%) and in one case of PRKAG2 syndrome. During the follow-up period, 17 (14.7%) children died; heart transplantation and cardioverter defibrillator implantation were performed in patients with Danon disease and PRKAG2 syndrome. Conclusion . Myocardial hypertrophy in children may be the first symptom of numerous non-sarcomeric monogenic diseases with varying etiologies, prognoses, and treatments. Understanding the features of the hypertrophic cardiomyopathy phenotype course allows for differential diagnosis before molecular genetic results are available and enables timely treatment adjustments. The introduction of high-throughput sequencing into clinical practice allows simultaneous analysis of a large number of genes causing the hypertrophic cardiomyopathy phenotype, opening new possibilities for early diagnosis of rare diseases in children and providing a better evidence base for further research.

  • Open Access

    Comparative efficacy of methods for early diagnosis of myocardial involvement in Duchenne and Becker muscular dystrophies

    by Валентина Геннадьевна Каверина, Наталия Андреевна Сдвигова, Ирина Вячеславовна Сильнова, София Георгиевна Попович, Евгения Владимировна Увакина, Елена Николаевна Басаргина, Людмила Михайловна Кузенкова

    Introduction. Cardiomyopathy is the leading cause of mortality in dystrophinopathies. Standard screening methods often fail to detect early preclinical changes. The aim of the study was a comparative assessment of the diagnostic value of modern methods (global longitudinal strain — GLS, 24-hour ECG monitoring — Holter monitoring, myocardial damage biomarkers) in detecting early cardiac dysfunction.Materials and methods. A prospective cross-sectional study included thirty one patient with Duchenne/Becker muscular dystrophy (DMD/BMD). All patients underwent comprehensive assessment including echocardiography with GLS analysis, 24-hour Holter monitoring, determination of NT-proBNP and troponin I levels.Results. Reduced left ventricular ejection fraction (LVEF < 50%) was detected in 5 patients (16.1%). In patients with preserved LVEF, subclinical reduction in GLS was noted in 68.8%. Holter monitoring detected tachycardia significantly more often than a single ECG recording (p < 0.050), as well as a combination of tachycardia with reduced heart rate variability and high ventricular ectopic activity. The NT-proBNP level was significantly higher in the group with LVEF < 50% (279.8 [73.28; 844.8] vs. 60.83 [34.24; 104.5] pg/mL, p = 0.020).Conclusion. Speckle-tracking echocardiography and 24-hour Holter monitoring have significantly higher sensitivity in detecting preclinical cardiomyopathy in DMD/BMD compared to standard screening. Their combined use with the determination of NT-proBNP and troponin I allows the risk stratificating and justifying early initiation of cardioprotective therapy.Contributions:Kaverina V.G. — writing the text;Sdvigova N.A. — writing, editing the text;Silnova I.V. — writing, editing the text;Popovich S.G. — writing, editing the text;Uvakina E.V. — writing, editing the text;Basargina E.N. — conception and design of the article, writing the text, editing;Kuzenkova L.M. — conception and design of the article, writing the text, editing.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: December 1, 2025Accepted: December 22, 2025Published: January 31, 2026


  • Open Access

    Clinical and molecular genetic characteristics of 19 Russian patients with Noonan syndrome caused by variants in the RAF1

    by Валентина Геннадьевна Каверина, Лейла Ахатовна Гандаева, Елена Николаевна Басаргина, Юлия Игоревна Давыдова, Александр Алексеевич Пушков, Kirill V. Savostyanov

    Introduction. RASopathy pathologies are a unique group of diseases with a multisystem lesion. In the structure of RASopathy, causal genetic variants of the RAF1 are the most common cause of HCM. Among all registered variants of the RAF1, the variant c.770C>T, p.S257L accounts for approximately 50% of cases. Due to the heterogeneity of clinical manifestations in patients with pathogenic variants of the RAF1 gene, the establishment of clinical and genetic features remains an urgent task. The aim of the study. To establish clinical and molecular genetic characteristics of Russian children with Noonan syndrome caused by variants of the RAF1 gene. Materials and methods. Single-center retrospective and prospective cohort study of a sample of ninety eight RASopathy patients aged from 1 month to 18 years. Results. In 19 of 98 patients with RASopathy, there were detected causal variants in the RAF1 gene, which amounted to 19.0%. All genetic variants detected in the RAF1 gene are localized in the cluster part of the gene in the CR2 domain. The c.770C>T, p.S257L variant was the cause of the disease in 10.22% of cases of all RASopathy diagnosed by us and 52.6% of cases of all children with RAF1 gene variants. All patients with RAF1 gene variants showed characteristic extracardiac signs of Noonan syndrome from the first months of life. Myocardial hypertrophy (MCH) was present in all patients, in the vast majority (89.4%) — with LVOT obstruction. When analyzing the course of remodeling, cases of MCH progression were more often noted (78.9%). In 35.7% of patients, one of the adverse cardiovascular events was recorded. Patients with the c.770C >T, p.S257L variant, compared with patients with other genetic variants, already from the first hospitalization demonstrated a more severe phenotype with pronounced signs of HF (p = 0.104), the highest level of NTproBNP (p = 0.003) and LVOTO (p = 0.040). Conclusion. RAF1 gene variants children demonstrate the classic phenotype of Noonan syndrome with the most severe damage to the cardiovascular system and require a comprehensive and dynamic examination with the involvement of specialists of various profiles.

  • Open Access

    A Unique Case of a Child with Two Rare Hereditary Diseases: Familial Dilated Cardiomyopathy and Arterial Calcification

    by Yulia Burykina, Daria Chudakova, Olga Zharova, Elena Basargina, Irina Silnova, Natalia Sdvigova, Leila Gandaeva, Yulia Davydova, Valentina Kaverina, Ilya Zhanin, et al.

    Here, we present a unique case of the combination of two rare hereditary diseases—a familial form of dilated cardiomyopathy (DCM) and arterial calcification (AC)—in a 10-month-old boy. DCM was caused by a novel pathogenic nucleotide variant (NV) c.542G>T in the MYH7 gene, and AC was caused by biallelic nucleotide variants c.3421C>T and c.4015C>T in the ABCC6 gene. NVs were identified by the next-generation sequencing (NGS) of a broad panel of 404 genes potentially involved in cardiovascular disorders and subsequently validated by Sanger sequencing in the proband and his parents. Cardiologic examinations confirmed the familial nature of cardiomyopathy and the pathogenicity of variant c.542G>T in MYH7 gene. This case highlights the clinical utility of NGS in identifying complex co-existing hereditary conditions and emphasizes the need for the comprehensive genetic testing of patients with atypical clinical presentations.


  • Open Access

    A rare case of Noonan syndrome associated with biallelic variants in the LZTR1

    by Leila A. Gandaeva, Валентина Геннадьевна Каверина, Elena N. Basargina, Alexander A. Pushkov, Kirill V. Savostyanov

    Introduction. Noonan syndrome is a clinically and genetically heterogeneous disease with multiple organ involvement associated with mutations in the genes of the RAS/MAPK signalling pathway. Most patients with Noonan syndrom (up to 50–80%) have disorders of the cardiovascular system, presented by a wide range of congenital heart defects and/or cardiomyopathy, predominantly hypertrophic phenotype. Thanks to the introduction of high-throughput sequencing, knowledge of the genetic causes of Noonan syndrome has expanded significantly, so since 2014, the LZTR1 gene (OMIM 601247) has been included in the list of genes responsible for the development of Noonan syndrome. The nucleotide variants of this gene are known to be inherited both in an autosomal dominant and autosomal recessive manner. However, the number of reports describing the clinical and genetic characteristics of patients with LZTR1 gene mutations is scarce in the world scientific literature. Objective. To describe the clinical features of Noonan syndrome with an autosomal recessive type of inheritance caused by biallelic variants c.1259A>G (p.Q420R) and c.2051T>C (p.I684T) in the LZTR1 gene. Materials and methods. A detailed analysis of the history data, the results of clinical, laboratory, and instrumental studies, a molecular genetic study using high-throughput sequencing technology and direct Sanger sequencing was carried out. After verifying the biallelic variants in the proband, a search was made for the identified nucleotide substitutions in the venous blood samples of the parents and sibs. Results. The article presents the data of a clinical observation of a rare case of Noonan syndrome caused by pathogenic variants in the LZTR1 gene with an autosomal recessive type of inheritance by the Department of Cardiology of the National Medical Research Center for Children’s Health of the Ministry of Health of Russia. Conclusion. The diversity of clinical manifestations makes it difficult to diagnose Noonan syndrome based on phenotype alone. The possibility of using high-throughput sequencing improves the quality of diagnostics, contributes to the replenishment of data on new pathogenic variants and the establishment of genotype-phenotypic correlations.


  • A new nucleotide variant in the ELAC2 gene in a young child with a ventricular hypertrophy

    by L. A. Gandaeva, E. N. Basargina, O. B. Kondakova, V. G. Kaverina, A. A. Pushkov, O. P. Zharova, P. P. Fisenko, K. V. Savostyanov

    The few foreign papers of the last decade have shown the relationship of various pathogenic variants of the ELAC2 gene to heterogeneous phenotypic manifestations, for which the unfavorable prognosis is common, caused by severe cardiomyopathy in the first year of life. The article presents the first clinical observation of a rare variant of the hypertrophic phenotype cardiomyopathy with a fatal outcome in the first year of life, and variants c.887T>C, p.L296P and c.1979A>T, p.K660I of the ELAC2 gene in Russia.The purpose of the work is to present clinical observation of a child with an early manifestation of a hypertrophic phenotype of cardiomyopathy caused by pathogenic variants of the ELAC2 gene.


  • Open Access

    Danon disease in children: view of a pediatric cardiologist

    by L. A. Gandaeva, E. N. Basargina, O. P. Zharova, K. A. Zubkova, A. A. Pushkov, V. G. Kaverina, V. I. Barsky, A. P. Fisenko, K. V. Savostyanov

    Danon disease is a rare hereditary disease with predominant damage to the heart and skeletal muscles. Danon disease is referred to lysosomal storage disorders with severe, progressive course and it often leads to an early mortality. The main cause of Danon disease is the mutations in the LAMP2 gene in the Xq24–q25 chromosome region. Danon disease has X-linked dominant nature of inheritance; women have a milder phenotype with older heart damage. For the first time the disease was described in boys with cardiomyopathy, severe skeletal myopathy and intellectual deficiency. The article presents up-to-date review on Danon disease and case reports of the cardiology department of the National Medical Research Center for Children’s Health, where 5 male patients were observed from 2014 to 2020, and the average age at diagnosis – 13,2 years. During the lab examination three patients demonstrated a significant increase of the heart failure marker (NT-proBNP) – more than 5 thousand pg/ml, the intracellular enzymes was more than 2,5 norms in 4 patients. The Wolff–Parkinson–White phenomenon is recorded in all patients on the ECG. Echocardiography in one patient showed a rare combination of myocardial hypertrophy and non-compact left ventricular myocardium. 2 patients had a combination of hypertrophic and dilated phenotypes with a reduced ejection fraction on Echo and severe myocardial fibrosis on MRI of the heart, which clinically manifested with chronic heart failure refractory to drug therapy, which required heart transplantation.